Plain-English translation of NCT07218783 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new implant called the , combined with a special lens called the SpyGlass IOL, works better and is safer than daily eye drops for treating glaucoma. You would receive this implant during cataract surgery if you qualify. The study will compare how well this new treatment works compared to the standard eye drop treatment (timolol).
Many people with glaucoma struggle to remember to use eye drops every day, and some drops don't work well enough to control eye pressure. This trial is testing whether a long-acting implant placed during cataract surgery could offer a better, easier way to manage glaucoma without daily drops.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to receive the new treatment, you would have cataract surgery where surgeons place the Bimatoprost implant and special lens in your eye at the same time. If you are assigned to the comparison group, you would use timolol eye drops daily as you normally would. Both groups would have follow-up visits so researchers can monitor how well the treatment works and check for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States